Breast Cancer Research and Treatment

, Volume 37, Issue 1, pp 29–37 | Cite as

In vitro effects of eicosanoid synthesis inhibitors in the presence of linoleic acid on MDA-MB-231 human breast cancer cells

  • Mitsuharu Earashi
  • Masakuni Noguchi
  • Motohiro Tanaka


We investigated the effects of cyclooxygenase and lipoxygenase inhibitors in the presence of linoleic acid (LA), as well as the direct effects of prostaglandin E (PGE) and leukotriene B (LTB) on a human breast cancer cell line (MDA-MB-231)in vitro. Piroxicam, esculetin, and nordihydroguaiaretic acid (NDGA) suppressed cell growth and thymidine incorporation. However, a low concentration (1 µg/ml) of indomethacin (INDO) stimulated cell growth and thymidine incorporation, while a high concentration of INDO (30 µg/ml) inhibited both. Esculetin and NDGA reduced the secretion of LTB, whereas piroxicam reduced the secretion of PGE. INDO reduced the secretion of PGE, but a low concentration of INDO increased the secretion of LTB. Consequently, cell growth was correlated with the PGE and/or LTB concentrations when the cells were treated with these cyclooxygenase or lipoxygenase inhibitors. On the other hand, exogenous PGE2 partially reversed the inhibition of thymidine incorporation caused by INDO, whereas LTB4 exerted a similar effect in the case of esculetin or NDGA. The reversibility of the piroxicam effect with PGE2 is not convincing. Therefore, it is suggested that the growth of MDA-MB-231 cellsin vitro is affected by both the lipoxygenase and cyclooxygenase products, probably the other eicosanoids rather than PGE2 and LTB4.

Key words

breast cancer esculetin indomethacin linoleic acid NDGA piroxicam 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hirayama T: Epidemiology of breast cancer with special reference to the role of diet. Prev Med 7: 173–195, 1978PubMedGoogle Scholar
  2. 2.
    Wynder EL, Rose DP, Cohen LA: Diet and breast cancer in causation and therapy. Cancer 58: 1804–1813, 1986PubMedGoogle Scholar
  3. 3.
    Hill P, Wynder EL: Comparison of mammary adipose fatty acid composition in Japanese and American breast cancer patients. Eur J Cancer Clin Oncol 23: 407–410, 1987PubMedGoogle Scholar
  4. 4.
    Welsch CW, Aylsworth CF: Enhancement of murine mammary tumorigenesis by feeding high levels of dietary fat: A hormonal mechanism? J Natl Cancer Inst 70: 215–221, 1983PubMedGoogle Scholar
  5. 5.
    Carter CA, Milholland RJ, Shea W, Ip MM: Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res 38: 3559–3562, 1983Google Scholar
  6. 6.
    McCormick DL, Madigan MJ, Moon RC: Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 45: 1803–1808, 1985PubMedGoogle Scholar
  7. 7.
    McCormick DL, Moon RC: Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal anti-inflammatory agent. Br J Cancer 48: 859–861, 1983PubMedGoogle Scholar
  8. 8.
    Hillyard LA, Abraham S: Effect of dietary polyunsaturated fatty acids on growth of mammary adenocarcinomas in mice and rats. Cancer Res 39: 4430–4437, 1979PubMedGoogle Scholar
  9. 9.
    Fulton AM:In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res 44: 2416–2420, 1984PubMedGoogle Scholar
  10. 10.
    Fulton AM, Heppner GH: Relationships of prostaglandin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas. Cancer Res 45: 4779–4784, 1985PubMedGoogle Scholar
  11. 11.
    Kollmorgen GM, King MM, Kosanke SD, Do C: Influence of dietary fat and indomethacin on the growth of transplantable mammary tumors in rats. Cancer Res 43: 4714–4719, 1983PubMedGoogle Scholar
  12. 12.
    Nagasawa H, Naito T: Inhibition by indomethacin of spontaneous mammary tumorigenesis in SHN mice. Breast Cancer Res Treat 8: 249–255, 1986PubMedGoogle Scholar
  13. 13.
    Hubbard NE, Chapkin RS, Erickson KL: Inhibition of growth and linoleate-enhanced metastasis of a transplantable mouse mammary tumor by indomethacin. Cancer Lett 43: 111–120, 1988PubMedGoogle Scholar
  14. 14.
    Carter CA, Ip MM, Ip C: A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid. Carcinogenesis 10: 1369–1374, 1989PubMedGoogle Scholar
  15. 15.
    Feldman JM, Hill R: Failure of indomethacin to inhibit growth of the R3230 mammary tumor in rats. J Natl Cancer Inst 75: 751–756, 1985PubMedGoogle Scholar
  16. 16.
    Noguchi M, Taniya T, Koyasaki N, Kumaki T, Miyazaki I, Mizukami Y: Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in Spague-Dawley rats fed a high- or low-fat diet. Cancer Res 51: 2683–2689, 1991PubMedGoogle Scholar
  17. 17.
    Noguchi M, Ohta N: Influences of high dietary fat and/or indomethacin on tumor proliferation and cell kinetics of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats. In Vivo 7: 53–58, 1993PubMedGoogle Scholar
  18. 18.
    Rose DP, Connolly JM: Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res 50: 7139–7144, 1990PubMedGoogle Scholar
  19. 19.
    Buckman DK, Hubbard NE, Erickson KL: Eicosanoids and linoleate-enhanced growth of mouse mammary tumor cells. Prostaglandins Leukot Essent Fatty Acids 44: 177–184, 1991PubMedGoogle Scholar
  20. 20.
    Kitagawa H, Noguchi M: Comparative effects of piroxicam and esculetin on incidence, proliferation, and cell kinetics of mammary carcinomas induced by 7,12-dimethylbenz(a)anthracene in rats on high and low fat diets. Oncology 51: 401–410, 1994PubMedGoogle Scholar
  21. 21.
    Abou-El-Ela SH, Prasse KW, Farrell RL, Carroll RW, Wade AE, Bunce OR: Effects of D,L-2-difluoromethylornithine and indomethacin on mammary tumor promotion in rats fed high n-3 and/or n-6 fat diets. Cancer Res 49: 1434–1440, 1989PubMedGoogle Scholar
  22. 22.
    Mosmann T: Rapid colorimetric assay for cellular growth and survival. Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63, 1983PubMedGoogle Scholar
  23. 23.
    Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47: 936–942, 1987PubMedGoogle Scholar
  24. 24.
    Carrol KK, Knor HT: Effects of dietary fat and dose level of 7,12-dimethylbenz(a)anthracene on mammary tumor incidence in rats. Cancer Res 30: 2260–2264, 1970PubMedGoogle Scholar
  25. 25.
    Hopkin GJ, West CE, Hard CC: Effect of dietary fats on the incidence of 7,12-dimethylbenz(a)anthracene-induced tumors in rats. Lipids 11: 328–333, 1976PubMedGoogle Scholar
  26. 26.
    Ip C: Ability of dietary fat to overcome the resistance of mature female rats to 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis. Cancer Res 40: 2785–2789, 1980PubMedGoogle Scholar
  27. 27.
    Aylsworth CF, Jone C, Trosko JE, Meites J, Welsch CW: Promotion of 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis by high dietary fat in the rat: Possible role of intercellular communication. J Natl Cancer Inst 72: 637–645, 1984PubMedGoogle Scholar
  28. 28.
    Brunda MJ, Herberman RB, Holden HT: Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 124: 2682–2687, 1980PubMedGoogle Scholar
  29. 29.
    Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: Prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64: 1061–1070, 1980PubMedGoogle Scholar
  30. 30.
    Karmali RA: Fatty acids: Inhibition. Am J Clin Nutr 45: 225–229, 1987PubMedGoogle Scholar
  31. 31.
    Karmali RA: Eicosanoids in neoplasia. Prev Med 16: 493–502, 1987PubMedGoogle Scholar
  32. 32.
    Lee PP, Ip MM: Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostaglandins Leukot Essent Fatty Acids 45: 21–31, 1992PubMedGoogle Scholar
  33. 33.
    Snyder DS, Castro R, Desforges JF: Antiproliferative effects of lipoxygenase inhibitors on malignant human hematopoietic cell lines. Exp Hematol 17: 6–9, 1989PubMedGoogle Scholar
  34. 34.
    Parker CW: Leukotrienes and prostaglandins in the immune system. In: Zor U, Naor Z, Kohen F (eds) Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 16. Raven Press, New York, 1986, pp 113–134Google Scholar
  35. 35.
    Earashi M, Noguchi M, Kinoshita K, Tanaka M: Effects of eicosanoid inhibitors on thein vitro growth and prostaglandin E and leukotriene B secretion of a human breast cancer cell line. Oncology 52: 150–155, 1995PubMedGoogle Scholar
  36. 36.
    Rose DP, Connolly JM: Stimulation of growth of human breast cancer cell lines in culture by linoleic acid. Biochem Biophys Res Commun 164: 277–283, 1989PubMedGoogle Scholar
  37. 37.
    Kidwell WR, Monaco ME, Wicha WS, Smith GS: Unsaturated fatty acid requirements for growth and survival of a rat mammary tumor cell line. Cancer Res 38: 4091–4100, 1978PubMedGoogle Scholar
  38. 38.
    Wicha MS, Liotta LA, Kidwell WR: Effects of free fatty acids on the growth of normal and neoplastic rat mammary epithelial cells. Cancer Res 39: 426–435, 1979PubMedGoogle Scholar
  39. 39.
    Vanderhoek JK, Ekborg SL, Bailey JM: Effects of cell growth, differentiation and transformation: Clinical involvement of leukotrienes. J Allergy Clin Immunol 74: 412–417, 1984PubMedGoogle Scholar
  40. 40.
    Fulton AM: Effects of indomethacin on the growth of cultured mammary tumors. Int J Cancer 33: 375–379, 1984PubMedGoogle Scholar
  41. 41.
    Bayer BM, Kruth HS, Vaughan M, Beaven MA: Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin. J Pharmacol Exp Ther 210: 106–111, 1979PubMedGoogle Scholar
  42. 42.
    Hial V, DeMello MCF, Horakova Z, Beaven MA: Antiproliferative activity of anti-inflammatory drugs in two mammalian cell culture lines. J Pharmacol Exp Ther 202: 446–454, 1977PubMedGoogle Scholar
  43. 43.
    Hobbs DC: Pharmacokinetics of piroxicam in man. Eur J Rheum Inflamm 6: 46–55, 1983Google Scholar
  44. 44.
    Carty TJ, Stevens JS, Lombardino JG, Parry MJ, Randall MJ: Piroxicam, a structurally novel anti-inflammatory compound. Mode of prostaglandin synthesis inhibition. Prostaglandins 19: 671–682, 1980PubMedGoogle Scholar
  45. 45.
    Dahl SL, Ward JR: Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent. Pharmacotherapy 2: 80, 1982PubMedGoogle Scholar
  46. 46.
    Neichi T, Koshihara Y, Murota S: Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesis. Biochim Biophys Acta 753: 130–132, 1983PubMedGoogle Scholar
  47. 47.
    Maloff BL, Fefer D, Cooke GM, Ackerman NR: Inhibition of LTB4 binding to human neutrophils by nordihydroguaiaretic acid. Agents Action 21: 358–360, 1987Google Scholar
  48. 48.
    McCormick DL, Spicer AM: Nordihydroguaiaretic acid suppression of rat mammary carcinogenesis induced by Nmethyl-N-nitrosourea. Cancer Lett 37: 139–146, 1987PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Mitsuharu Earashi
    • 1
  • Masakuni Noguchi
    • 1
    • 2
  • Motohiro Tanaka
    • 3
  1. 1.Department of Surgery (II)Kanazawa University Hospital, School of MedicineJapan
  2. 2.The Operation CenterKanazawa University Hospital, School of MedicineKanazawaJapan
  3. 3.Department of Experimental TherapeuticsCancer Research Institute, Kanazawa UniversityKanazawaJapan

Personalised recommendations